Carfizome (Carfilzomib) Injection

Description

Description

This page contains brief details about the drug carfilzomib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Carfilzomib is an anticancer medication containing the active constituent carfilzomib. It is used to treat a type of cancer called multiple myeloma. Multiple myeloma is a cancer of a white blood cell called the plasma cell. These cells grow uncontrolled and accumulate in the bone marrow, damaging the bones and kidneys. The treatment with this medication reduces symptoms of multiple myelomas, such as bone pain, fatigue, and anemia, improving a patient’s quality of life.

Carfilzomib was approved by the FDA on July 20, 2012, as a treatment for patients with multiple myeloma who have not responded to at least two prior therapies or whose disease has progressed within 60 days of completion of the last therapy. It is often used in combination with other medications.

Mechanism of Action of Carfilzomib

Carfilzomib is a proteasome inhibitor, which means it works by blocking the action of proteasomes, the enzymes responsible for breaking down proteins in cells. By blocking proteasomes, this medication can prevent the growth and survival of cancer cells, ultimately leading to the death of cancer cells. This can slow or stop the progression of multiple myeloma and may improve survival rates for some patients.

Uses of Carfilzomib

Carfilzomib is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.

Carfilzomib Dosage available

Carfilzomib is typically administered as an intravenous (IV) injection by a healthcare provider. The exact dosing and frequency of administration will depend on the specific condition being treated and other individual factors, such as the patient’s age, weight, and overall health. If a dose is missed, it’s important to contact your healthcare provider as soon as possible. Suppose the missed dose is discovered within a few hours of the scheduled time. In that case, your healthcare provider may recommend administering the missed dose as soon as possible while maintaining the usual interval between doses. However, if more than a few hours have passed since the missed dose, your healthcare provider may recommend skipping the missed dose and resuming the regular dosing schedule at the next scheduled time. Avoid double-up on doses to make up for a missed one.